What is the recommended approach for diagnosing and managing an acute gout flare?

Acute Gout Flare: Diagnosis and Management

For definitive diagnosis, identify monosodium urate (MSU) crystals via joint aspiration and synovial fluid analysis under polarized light microscopy; however, if aspiration is not feasible, diagnose clinically based on podagra, elevated serum urate, and rapid response to treatment, supplemented by ultrasound or dual-energy CT imaging. 1, 2

Diagnosis

Gold Standard

• Joint aspiration with MSU crystal identification is the definitive diagnostic method 1
• Synovial fluid examination under polarized light microscopy confirms needle-shaped, negatively birefringent crystals

Clinical Diagnosis (When Aspiration Not Feasible)

You can make a clinical diagnosis when the patient presents with:

• Podagra (first metatarsophalangeal joint involvement) - highest diagnostic utility among clinical features 1
• Elevated serum uric acid (though note: SUA can be normal during acute flares - this does NOT exclude gout) 3
• Rapid response to colchicine therapy 1
• Presence of tophi 1

Critical Pitfall: Serum uric acid levels may be normal or even low during acute attacks due to uricosuric effects of inflammation. Do not rely solely on SUA for diagnosis 3

Imaging Support

• Ultrasound: Detects double contour sign and tophi
• Dual-energy CT: Superior diagnostic performance, visualizes MSU deposits 1
• Standard X-rays have low diagnostic utility 4

Essential Screening at Diagnosis

Screen all patients for comorbidities 2:

• Calculate estimated GFR for renal function
• Assess cardiovascular risk factors (hypertension, diabetes, hyperlipidemia)
• Screen for coronary heart disease, heart failure, stroke risk
• Evaluate for obesity and metabolic syndrome

Management of Acute Flare

Timing is Critical

Treat within 12 hours of symptom onset for maximum efficacy - educate patients to self-medicate at first warning symptoms ("pill in pocket" approach) 2

First-Line Treatment Options

Choose based on contraindications, comorbidities, and patient factors - all three options have similar efficacy:

1. Colchicine (within 12 hours of onset)

• Dosing: 1 mg loading dose, then 0.5 mg one hour later on day 1, followed by 0.5 mg 2-3 times daily 2, 5
• Advantages: Effective when given early
• Contraindications/Cautions:
  • Severe renal impairment (reduce dose in CKD)
  • Concurrent use of strong P-glycoprotein or CYP3A4 inhibitors (cyclosporin, clarithromycin) - absolutely avoid 2
  • Stop immediately if diarrhea develops (first sign of toxicity) 5
  • Monitor for neurotoxicity/myotoxicity, especially with statins 2

2. NSAIDs (with PPI if appropriate)

• Any NSAID is acceptable - no evidence that indomethacin is superior to naproxen or ibuprofen 6
• Contraindications: Severe renal impairment, heart failure, cirrhosis, active GI disease 2, 6

3. Corticosteroids

• Oral: Prednisolone 30-35 mg/day for 3-5 days 2
• Intra-articular: Joint aspiration followed by corticosteroid injection 2
• Intramuscular: Alternative route 1
• Advantages: Generally safer with fewer adverse effects than NSAIDs, low cost 6
• The ACP 2017 guideline suggests corticosteroids as first-line due to superior safety profile 6
• Contraindications: Systemic fungal infections 6

Combination Therapy

For severe polyarticular flares, consider combining colchicine with NSAIDs or corticosteroids 2

Second-Line: IL-1 Blockers

• Reserved for patients with frequent flares AND contraindications to all first-line options 2
• Contraindication: Active infection 2
• Monitor neutrophil count 5

Patient Education (Essential Component)

Educate every patient about 2:

• Gout is a curable chronic disease requiring lifelong management
• Pathophysiology: MSU crystal deposition from hyperuricemia
• Acute flare treatment is separate from long-term urate-lowering therapy
• Self-medication strategy for future flares
• Associated comorbidities and cardiovascular risks

Lifestyle Modifications

Advise all patients 2, 1:

• Weight loss if overweight
• Avoid: Alcohol (especially beer and spirits), sugar-sweetened drinks, excessive meat and seafood
• Encourage: Low-fat dairy products, regular exercise
• Smoking cessation

Urate-Lowering Therapy (ULT) Considerations

When to Discuss ULT

Discuss ULT at first presentation but timing of initiation depends on individual factors 2:

Strong indications for early ULT initiation:

• Recurrent flares (≥2 per year)
• Tophi present
• Urate arthropathy
• Renal stones
• Young age at onset (<40 years)
• Very high SUA (>8 mg/dL or 480 μmol/L)

The ACP 2017 guideline recommends AGAINST initiating long-term ULT after first attack or infrequent attacks (<2/year) 6

Flare Prophylaxis When Starting ULT

Mandatory prophylaxis for first 6 months of ULT 2:

• First choice: Colchicine 0.5-1 mg/day (reduce dose in renal impairment) 2, 1
• Alternatives: Low-dose NSAIDs or low-dose glucocorticoids if colchicine contraindicated 2, 1
• Continue prophylaxis for at least 3-6 months, with ongoing evaluation 7

Timing of ULT Initiation During Flare

You can start ULT during an acute flare - it does not prolong or worsen the attack 7. The 2020 ACR guideline conditionally recommends starting during the flare for time efficiency and patient motivation, though this remains a patient-specific decision 7.

ULT Target

• Standard target: SUA <6 mg/dL (360 μmol/L) 1
• Severe gout target (tophi, chronic arthropathy, frequent attacks): SUA <5 mg/dL (300 μmol/L) until crystal dissolution 2
• Avoid long-term SUA <3 mg/dL due to potential neuroprotective effects of uric acid 2

This algorithmic approach prioritizes early treatment, patient education, and individualized therapy selection based on contraindications and comorbidities to optimize outcomes and prevent long-term joint damage.